# A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

> **NCT05352516** · PHASE3 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 514 (actual)

## Conditions studied

- Postmenopausal

## Interventions

- **BIOLOGICAL:** HLX14
- **BIOLOGICAL:** Prolia®

## Key facts

- **NCT ID:** NCT05352516
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-17
- **Primary completion:** 2023-12-17
- **Final completion:** 2024-07-03
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05352516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05352516, "A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05352516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*